Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
M. Raschid Hoda, Mario W. Kramer, Axel S. Merseburger & Marcus V. Cronauer. (2017) Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer. Expert Opinion on Pharmacotherapy 18:1, pages 105-113.
Read now
Read now
Zinelabidine Abouelfadel & E David Crawford. (2008) Leuprorelin depot injection: patient considerations in the management of prostatic cancer. Therapeutics and Clinical Risk Management 4:2, pages 513-526.
Read now
Read now
Agata A Exner & Gerald M Saidel. (2008) Drug-eluting polymer implants in cancer therapy. Expert Opinion on Drug Delivery 5:7, pages 775-788.
Read now
Read now
Articles from other publishers (24)
Tingting Hu, Hanlin Gong, Jiayue Xu, Yuan Huang, Fengbo Wu & Zhiyao He. (2022) Nanomedicines for Overcoming Cancer Drug Resistance. Pharmaceutics 14:8, pages 1606.
Crossref
Crossref
Selva Jeganathan, Emily Budziszewski, Peter Bielecki, Michael C. Kolios & Agata A. Exner. (2020) In situ forming implants exposed to ultrasound enhance therapeutic efficacy in subcutaneous murine tumors. Journal of Controlled Release 324, pages 146-155.
Crossref
Crossref
S. Rahima Benhabbour, Martina Kovarova, Clinton Jones, Daijha J. Copeland, Roopali Shrivastava, Michael D. Swanson, Craig Sykes, Phong T. Ho, Mackenzie L. Cottrell, Anush Sridharan, Samantha M. Fix, Orrin Thayer, Julie M. Long, Daria J. Hazuda, Paul A. Dayton, Russell J. Mumper, Angela D. M. Kashuba & J. Victor Garcia. (2019) Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery. Nature Communications 10:1.
Crossref
Crossref
Christopher Hernandez & Agata A Exner. (2017)
Predicting
in vivo
behavior of injectable,
in situ
-forming drug-delivery systems
. Therapeutic Delivery 8:7, pages 479-483.
Crossref
Crossref
Luis Solorio & Agata A. Exner. (2015) Effect of the Subcutaneous Environment on Phase-Sensitive In Situ-Forming Implant Drug Release, Degradation, and Microstructure. Journal of Pharmaceutical Sciences 104:12, pages 4322-4328.
Crossref
Crossref
Gaurav Joshi, Pankaj Kumar Singh, Arvind Negi, Anil Rana, Sandeep Singh & Raj Kumar. (2015) Growth factors mediated cell signalling in prostate cancer progression: Implications in discovery of anti-prostate cancer agents. Chemico-Biological Interactions 240, pages 120-133.
Crossref
Crossref
Dalsan You, Byung Ha Chung, Sang Eun Lee & Choung-Soo Kim. (2015) Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study. Prostate International 3:1, pages 22-26.
Crossref
Crossref
Seung-Hwan LeeHyun-Moo LeeSae-Woong KimEun-Sik LeeSung-Joon HongChoung-Soo KimTaek-Won KangByung-Ha Chung. (2014) Is High-Dose Leuprorelin Acetate Effective and Safe in Asian Men with Prostate Cancer? An Open-Label, Non-Comparative, Multi-Center Clinical Trial. Yonsei Medical Journal 55:2, pages 310.
Crossref
Crossref
Kuo-Pao Lai, Chiung-Kuei Huang, Yu-Jia Chang, Chin-Ying Chung, Shinichi Yamashita, Lei Li, Soo Ok Lee, Shuyuan Yeh & Chawnshang Chang. (2013) New Therapeutic Approach to Suppress Castration-Resistant Prostate Cancer Using ASC-J9 via Targeting Androgen Receptor in Selective Prostate Cells. The American Journal of Pathology 182:2, pages 460-473.
Crossref
Crossref
Jan-Erik Damber, Teuvo L.J. Tammela, Peter Iversen, Per-Anders Abrahamsson, Laurent Boccon-Gibod, Tine Kold Olesen, Egbert van der Meulen & Bo-Eric Persson. (2012) The Effect of Baseline Testosterone on the Efficacy of Degarelix and Leuprolide: Further Insights From A 12-Month, Comparative, Phase III Study in Prostate Cancer Patients. Urology 80:1, pages 174-181.
Crossref
Crossref
A Spitz, J M Young, L Larsen, C Mattia-Goldberg, J Donnelly & K Chwalisz. (2011) Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer. Prostate Cancer and Prostatic Diseases 15:1, pages 93-99.
Crossref
Crossref
Elena Chiocca, Eleonora Dati, Giampiero I. Baroncelli, Alessandra Cassio, Malgorzata Wasniewska, Fiorella Galluzzi, Silvia Einaudi, Marco Cappa, Gianni Russo & Silvano Bertelloni. (2012) Central Precocious Puberty: Treatment with Triptorelin 11.25 mg. The Scientific World Journal 2012, pages 1-6.
Crossref
Crossref
Arlene McDowell & Natalie J. Medlicott. 2012. Long Acting Injections and Implants. Long Acting Injections and Implants
57
71
.
Yun-Seok Rhee, MinJi Sohn, Byung H. Woo, B. C. Thanoo, Patrick P. DeLuca & Heidi M. Mansour. (2011) Sustained-Release Delivery of Octreotide from Biodegradable Polymeric Microspheres. AAPS PharmSciTech 12:4, pages 1293-1301.
Crossref
Crossref
Neal Shore. (2010) Introducing Vantas: The First Once-Yearly Luteinising Hormone-Releasing Hormone Agonist. European Urology Supplements 9:8, pages 701-705.
Crossref
Crossref
Luis Solorio, Brett M. Babin, Ravi B. Patel, Justyna Mach, Nami Azar & Agata A. Exner. (2010) Noninvasive characterization of in situ forming implants using diagnostic ultrasound. Journal of Controlled Release 143:2, pages 183-190.
Crossref
Crossref
Jiann-Jyh Lai, Kuo-Pao Lai, Kuang-Hsiang Chuang, Philip Chang, I-Chen Yu, Wen-Jye Lin & Chawnshang Chang. (2009) Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-α expression. Journal of Clinical Investigation 119:12, pages 3739-3751.
Crossref
Crossref
Mingshi Yang & Sven Frokjaer. 2009. Delivery Technologies for Biopharmaceuticals. Delivery Technologies for Biopharmaceuticals
9
28
.
Cristiana Angelucci, Gina Lama, Fortunata Iacopino, Silvia Ferracuti, Aldo V. Bono, Robert P. Millar & Gigliola Sica. (2009) GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors. Endocrine 36:1, pages 87-97.
Crossref
Crossref
Laurence Klotz, Laurent Boccon-Gibod, Neal D. Shore, Cal Andreou, Bo-Eric Persson, Per Cantor, Jens-Kristian Jensen, Tine Kold Olesen & Fritz H. Schröder. (2008) The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU International 102:11, pages 1531-1538.
Crossref
Crossref
Ramesh Rathi & Kirk Fowers. 2008. Modified-Release Drug Delivery Technology, Second Edition. Modified-Release Drug Delivery Technology, Second Edition
171
181
.
Ray Truant, Randy Singh Atwal & Anjee Burtnik. (2007) Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease. Progress in Neurobiology 83:4, pages 211-227.
Crossref
Crossref
Bertrand Tombal & Richard Berges. (2006) Eligard®: Advantages for Optimal Testosterone Control. European Urology Supplements 5:18, pages 900-904.
Crossref
Crossref
Oliver Sartor. (2006) Eligard® 6: A New Form of Treatment for Prostate Cancer. European Urology Supplements 5:18, pages 905-910.
Crossref
Crossref